ABSTRACT
An open pilot study on the safety and efficacy of melatonin in the treatment of insomniac patients was conducted in 22 subjects (16 females), mean +/- S.D. age 60.1 +/- 9.5 years. All patients received 3 mg of gelatin melatonin capsules per os daily for 6 months, 30 min before expected sleep time. Twenty of 22 patients were on benzodiazepine treatment and they continued this treatment for part of or for the entire melatonin administration period. Serum concentrations of prolactin, follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), or estradiol were measured by radioimmunoassay (RIA) in morning samples at the beginning and after 6 months of melatonin administration, and standard clinical laboratory tests for blood components were performed. Urinary 6-sulphatoxymelatonin (aMT6s) excretion was measured by RIA before treatment. Serum concentrations of prolactin, FSH, TSH, or estradiol did not exhibit changes after 6 months of melatonin administration, nor were any indications of hematologic or blood biochemistry alteration found. Melatonin augmented significantly the quality and duration of sleep, and decreased sleep latency and the number of awakening episodes, as assessed from sleep logs filled by the patients (first 21 days) and from structured interviews performed by incumbent physicians (up to 6 months). Estimates of next-day function (i.e., alertness in the morning and during the day) also improved significantly during melatonin treatment. The observed effect lasted for the entire period examined (up to 6 months), with 22 out of 22 patients showing improved sleep at the end of treatment. The urinary excretion of aMT6s before starting administration of melatonin correlated negatively and significantly with age, but not with the intensity of sleep the disorder or the outcome of treatment. In 13 of 20 patients taking benzodiazepines together with melatonin, benzodiazepine use could be stopped, and in another four patients, benzodiazepine dose could be decreased to 25-66% of the initial dose. The results of this open, subacute administration trial indicate that melatonin is a safe and useful treatment for sleep disturbances in middle-aged or elderly patients, either by itself or together with benzodiazepines.
Subject(s)
Benzodiazepines/administration & dosage , Estradiol/blood , Follicle Stimulating Hormone/blood , Melatonin/analogs & derivatives , Melatonin/therapeutic use , Prolactin/blood , Sleep Initiation and Maintenance Disorders/drug therapy , Thyrotropin/blood , Aged , Female , Humans , Male , Melatonin/urine , Middle Aged , Pilot Projects , Radioimmunoassay , Safety , Sleep Initiation and Maintenance Disorders/bloodABSTRACT
A decrease in nocturnal serum melatonin levels was reported in patients with clinically uncharacterized coronary artery disease. To assess whether there was a correlation between melatonin production and disease stage, we measured the nocturnal urinary excretion of 6-sulphatoxymelatonin (an index of blood melatonin concentration) in patients with chronic stable or unstable coronary disease and in a group of age-matched controls. Three groups of individuals were studied: a) 24 healthy subjects (mean age: 63 +/- 13 yr); b) 32 patients with chronic, stable, coronary disease (62 +/- 11 yr); and c) 27 patients with unstable angina (62 +/- 12 yr). For 6-sulphatoxymelatonin measurement, urine was collected from 18:00 to 06:00 hr, within 48 hr of hospitalization in the case of unstable angina. 6-Sulphatoxymelatonin was measured by a specific radioimmunoassay. Urinary 6-sulphatoxymelatonin excretion was significantly lower in unstable angina patients than in healthy subjects or in patients with stable angina. 6-Sulphatoxymelatonin correlated negatively with age in healthy subjects, but not in coronary patients. 6-Sulphatoxymelatonin excretion in patients treated with beta-adrenoceptor blockers did not differ significantly from coronary patients not receiving beta-blockers. The results indicate that patients with coronary disease have a low melatonin production rate, with greater decreases in those with higher risk of cardiac infarction and/or death.
Subject(s)
Coronary Disease/urine , Melatonin/analogs & derivatives , Melatonin/urine , Adult , Aged , Aged, 80 and over , Aging/urine , Female , Humans , Male , Middle Aged , RadioimmunoassayABSTRACT
The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients. Twenty-one consecutive patients with FM were included in an open 4-week-duration pilot study. Before and after treatment with melatonin 3 mg at bedtime, patients were evaluated using tender point count by palpation of 18 classic anatomical regions, pain score in four predesignated areas, pain severity on a 10 cm visual analogue scale (VAS), sleep disturbances, fatigue, depression, anxiety, and patient and physician global assessments, also by a VAS. Urine 6-sulphatoxymelatonin levels (aMT-6S) were measured in the patients and 20 age- and sex-matched controls. Nineteen patients completed the study. One patient withdrew because of migraine and another was lost to follow-up. At day 30, median values for the tender point count and severity of pain at selected points, patient and physician global assessments and VAS for sleep significantly improved with melatonin treatment. Other variables improved but did not reach statistical significance. Adverse events were mild and transient. Lower levels of aMT-6S were found in FM patients compared with normal median controls (+/-SD, 9.16 +/- 7.9 microg/24 h vs 16.8 +/- 12.8 microg/24 h) (p = 0.06). Although this is an open study, our preliminary results suggest that melatonin can be an alternative and safe treatment for patients with FM. Double-blind placebo controlled studies are needed.
Subject(s)
Anticonvulsants/therapeutic use , Fibromyalgia/drug therapy , Melatonin/therapeutic use , Administration, Oral , Adult , Aged , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacokinetics , Fatigue Syndrome, Chronic/drug therapy , Fatigue Syndrome, Chronic/etiology , Fatigue Syndrome, Chronic/metabolism , Female , Fibromyalgia/complications , Fibromyalgia/metabolism , Humans , Melatonin/administration & dosage , Melatonin/analogs & derivatives , Melatonin/pharmacokinetics , Melatonin/urine , Middle Aged , Pain/drug therapy , Pain/etiology , Pain/metabolism , Pain Measurement , Pilot Projects , Sleep Wake Disorders/drug therapy , Sleep Wake Disorders/etiology , Sleep Wake Disorders/metabolism , Treatment OutcomeABSTRACT
Melatonin is synthesized and secreted during the dark period of the light/dark cycle. The rhythmic nocturnal melatonin secretion is directly generated by the circadian clock, located within the suprachiasmatic nuclei in mammals and is entrained to a 24-hour period by the light-dark cycle. The periodic secretion of melatonin may be used as a circadian mediator to any system that can 'read' the message. Melatonin seems to act as an arm of the circadian clock, giving a time-related signal to a number of body functions; one of these, the circadian organization of the defense of the organism, is discussed in some detail as an example.
Subject(s)
Circadian Rhythm/immunology , Circadian Rhythm/physiology , Melatonin/immunology , Melatonin/physiology , Aging/immunology , Aging/physiology , Animals , Circadian Rhythm/drug effects , Humans , Melatonin/pharmacology , Pineal Gland/immunology , Pineal Gland/physiology , Rats , Signal Transduction/immunology , Signal Transduction/physiologyABSTRACT
In an open pilot study on the efficacy of melatonin in the treatment of sleep disorders, patients with sleep disturbances alone, patients with sleep disturbances and signs of depression and patients with sleep disorders and dementia received 3 mg melatonin p.o. for 21 days, at bed time. After 2-3 days of treatment, melatonin significantly augmented sleep quality and decreased the number of awakening episodes in patients with sleep disturbances associated or not with depression. Estimates of next-day alertness improved significantly only in patients with primary insomnia. Agitated behavior at night (sundowning) decreased significantly in dementia patients. In a second retrospective study, 14 Alzheimer's disease (AD) patients received 9 mg melatonin daily for 22-35 months. A significant improvement of sleep quality was found, while there were no significant differences between initial and final neuropsychological evaluation (Functional Assessment Tool for AD, Mini-Mental). The results indicate that melatonin can be useful to treat sleep disturbances in elderly insomniacs and AD patients.
Subject(s)
Melatonin/therapeutic use , Sleep Wake Disorders/drug therapy , Aged , Aged, 80 and over , Alzheimer Disease/complications , Dementia, Vascular/complications , Depression/complications , Female , Humans , Male , Melatonin/administration & dosage , Middle Aged , Psychomotor Agitation/complications , Psychomotor Agitation/drug therapy , Retrospective Studies , Sleep Initiation and Maintenance Disorders/complications , Sleep Initiation and Maintenance Disorders/drug therapy , Sleep Wake Disorders/complicationsABSTRACT
The effect of aging and melatonin on 24-h rhythms in tyrosine hydroxylase activity and 3H - choline conversion into 3H - acetylcholine were examined in cervical, stellate, coeliac-mesenteric and hypogastric ganglia, and in the adrenal medulla and heart of rats. Young (50 days old) and old (18 months old) rats received evening injections of 10 or 100 microg of melatonin or its vehicle for 17 days. In superior cervical, stellate and coeliac-superior mesenteric ganglia, as well as in the adrenal medulla, norepinephrine and acetylcholine synthesis attained maximal values at night (c.a. 2030-0100 h). In the hypogastric ganglion, maximal tyrosine hydroxylase activity occurred at night at both studied ages. Two maxima in acetylcholine synthesis were detected in hypogastric ganglion of young rats (c.a. 1300 h and 0100 h, respectively) while in old rats a single maximum was observed at noon. Cardiac tyrosine hydroxylase activity peaked at early night (c.a. 2200-2300 h) while cardiac acetylcholine synthesis peaked at the afternoon (c.a. 1700-1900 h). Old rats exhibited a significant decrease of rhythm amplitude and increase of mean values in tyrosine hydroxylase activity in autonomic ganglia and adrenal medulla, and abolition of tyrosine hydroxylase rhythm in the heart. Twenty-four hour rhythmicity in acetylcholine synthesis was impaired or abolished in aged rats. Treatment of old rats with 10 or 100 microg melatonin generally augmented amplitude of rhythms and reinduced the nocturnal peak of acetylcholine synthesis in the hypogastric ganglion. Only the high melatonin dose significantly augmented rhythm amplitude of tyrosine hydroxylase activity (superior cervical and coeliac-superior mesenteric ganglia) and acetylcholine synthesis (superior cervical, stellate and coeliac-superior mesenteric ganglia) in young rats. The results indicate that the activity of the central oscillator, driven to the organs in part via the autonomic nervous system, deteriorates significantly with aging and that melatonin may restore partially such a deterioration.
Subject(s)
Acetylcholine/biosynthesis , Adrenal Glands/metabolism , Aging/metabolism , Circadian Rhythm/physiology , Ganglia, Sympathetic/metabolism , Melatonin/pharmacology , Myocardium/metabolism , Norepinephrine/biosynthesis , Adrenal Glands/drug effects , Adrenal Glands/growth & development , Animals , Choline/metabolism , Circadian Rhythm/drug effects , Ganglia, Sympathetic/drug effects , Ganglia, Sympathetic/growth & development , Heart/drug effects , Heart/growth & development , Male , Rats , Rats, Sprague-Dawley , Tyrosine 3-Monooxygenase/metabolismABSTRACT
Young (50 days old) and old (18 months old) Sprague-Dawley rats were injected with mycobacterial Freund's adjuvant to produce an inflammatory disease of the joints and were studied the day before, and on days 6, 12 and 18 after injection. At every postinjection interval examined, old rats had significantly lower circadian amplitudes of pineal melatonin content. On day 18 of arthritis development, decreased levels of pineal melatonin were also seen in young rats. A second study, carried out 18 days after the injection of Freund's complete adjuvant and after 17 daily injections of 10 or 100 microg of melatonin in the evening, indicated that melatonin treatment restored the inflammatory response in old rats (assessed plethysmographically in hind paws) to the level found in young animals. In young rats, an inflammation-promoting effect of 100 microg melatonin could be demonstrated. As a consequence of the immune reaction, submaxillary lymph node and splenic ornithine decarboxylase activity (an index of lymph cell proliferation) augmented significantly, with acrophases of 24-hour rhythms in the afternoon for lymph nodes or in the morning for spleen. Mesor and amplitude of ornithine decarboxylase rhythm were lowest in old rats, while melatonin injection generally augmented its amplitude. Lymph node and splenic tyrosine hydroxylase activity (a presynaptic adrenergic marker) reached maximal values during early night hours while maximal values of [3H]acetylcholine synthesis (a presynaptic cholinergic marker) occurred during the afternoon in lymph nodes. Amplitude and mesor of these rhythms were lowest in old rats, an effect generally counteracted by melatonin treatment. The results suggest that inflammation is accompanied by an age-dependent, significant depression of pineal melatonin synthesis during adjuvant-induced arthritis and a decreased amplitude of the circadian rhythm of immune cell proliferation and autonomic activity in lymph nodes and spleen. These effects are counteracted by injection of melatonin, mainly in old rats.
Subject(s)
Acetylcholine/biosynthesis , Circadian Rhythm/drug effects , Lymph Nodes/drug effects , Melatonin/pharmacology , Norepinephrine/biosynthesis , Ornithine Decarboxylase/drug effects , Aging/metabolism , Animals , Arthritis, Experimental/metabolism , Lymph Nodes/metabolism , Male , Maxilla , Pineal Gland/drug effects , Pineal Gland/metabolism , Rats , Rats, Sprague-Dawley , Spleen/drug effects , Spleen/metabolism , Tyrosine 3-Monooxygenase/metabolismABSTRACT
Aging has been associated with attenuation of amplitude and changes in period of many circadian rhythms. The present study was carried out to examine, in young (50 days old) and old (18 months old) rats, whether 24-h rhythms of cell proliferation (as assessed by measuring ornithine decarboxylase activity) and of presynaptic adrenergic and cholinergic markers change in lymph nodes and spleen during Freund's adjuvant-induced arthritis. Groups of young and old Sprague-Dawley rats were studied the day before, and on days 6, 12 and 18 after Freund's adjuvant injection. On day 16 after adjuvant injection, inflammation of hind paws, mainly in the ankle joints, was less marked in old than in young rats. Lymph node and splenic ornithine decarboxylase activity exhibited significant 24-h variations with maximal activity during daily hours. Before treatment, enzyme activity values were significantly lower in old rats in both tissues examined. During the immune reaction, lymph node and splenic ornithine decarboxylase augmented 8-10-fold, with progressively smaller amplitude of daily variations as arthritis developed. In every case, mesor and amplitude of ornithine decarboxylase activity were lowest in old rats. Submaxillary lymph node and splenic tyrosine hydroxylase activity attained maximal values at night. At every time interval after mycobacterium adjuvant injection, amplitude and mesor of tyrosine hydroxylase activity rhythm were lowest in old rats. A maximum in submaxillary lymph node 3H-acetylcholine synthesis occurred at the afternoon. On day 6 and 12 after Freund's adjuvant injection, lymph node 3H-acetylcholine synthesis was significantly smaller in old rats. Day-night differences in submaxillary lymph node or splenic ornithine decarboxylase and tyrosine hydroxylase activities, or in submaxillary lymph node 3H-acetylcholine synthesis, of rats treated with the adjuvant's vehicle, did not differ significantly from those seen in untreated controls. The results are compatible with an age-dependent decline of immune-mediated inflammatory responses. The activity of the central circadian oscillator, driven to the organs in part via the autonomic nervous system, seems also to deteriorate during aging.
Subject(s)
Acetylcholine/biosynthesis , Aging/metabolism , Arthritis, Experimental/metabolism , Circadian Rhythm/physiology , Lymphoid Tissue/metabolism , Norepinephrine/biosynthesis , Ornithine Decarboxylase/metabolism , Animals , Lymph Nodes/metabolism , Male , Maxilla , Rats , Rats, Sprague-Dawley , Spleen/metabolism , Tyrosine 3-Monooxygenase/metabolismABSTRACT
Monozygotic twins with Alzheimer's disease of 8 years duration were studied. The onset of the disease differed by about 6 months between twins and was characterized by a primary impairment of memory function. Clinical evaluation at the time of diagnosis indicated a similar cognitive and neuroimaging alteration in both patients, as well as a similar neuropsychologic impairment. A possible genetic origin of the disease was suggested by a similar disease suffered by the mother. Patients were initially treated with vitamin E (800 I.U./day). Starting at approximately the same time (about 3 years ago), they received 50 mg/day thioridazine because of the behavioral and sleep disorder. One of the patients was treated with melatonin (6 mg orally) at bed time daily for 36 months. Evolution of the disease in the melatonin-treated patient indicated a milder impairment of memory function, with substantial improvement of sleep quality and reduction of sundowning. This led to discontinuance (after 3 months) of thioridazine treatment. Present clinical evaluation indicated a difference in functional stage of the disease between the twins (Functional Assessment Tool For Alzheimer's Disease, FAST), with a score of 5 in the twin who received melatonin and of 7b in the twin who did not receive it. Since experimental data on melatonin in animals indicated its antioxidant, antiapoptotic, and beta-amyloid-decreasing activity, the hypothesis that melatonin has a beneficial effect in Alzheimer's disease patients should be considered.